Trial
NCT00910000
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital; Massachusetts General Hospital; Merck Sharp & Dohme LLC
Condition
Ovarian Cancer
Intervention
Vorinostat
Why stopped
Terminated due to unacceptable toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-10